Start: June 19, 2020
End: August 2025
Enrollment: 500
This Phase 2 clinical trial (TRAILBLAZER-ALZ 2) will test whether donanemab, also known as LY3002813, is safe and effective to slow cognitive impairment and reduce amyloid plaque in people with symptoms of early-stage Alzheimer's disease. Participants will be randomly assigned to receive injections of donanemab or a placebo. The study will last about 133 weeks and may include up to 26 visits. The researchers will measure cognition as well as changes in the brain, such as amyloid plaque build-up, using MRI and positron emission tomography (PET) brain imaging scans.
Minimum Age: 60 Years
Maximum Age: 85 Years
Contact study personnel listed either under the general study contact or the location nearest you.
Who Is the General Study Contact?
For more information, visit the study website: TRAILBLAZER-ALZ 2.
Contact NIA’s Alzheimer’s and related Dementias Education and Referral (ADEAR) Center at 800-438-4380 or email ADEAR.
Lead: Eli Lilly and Company
Source: ClinicalTrials.gov ID: NCT04437511
An official website of the U.S. government, managed by the National Institutes on Aging at the National Institutes of Health